



**National Institute for
Health and Clinical Excellence**

MidCity Place
71 High Holborn
London
WC1V 6NA

Tel: 0845 003 7780
Fax: 0845 003 7784

Email: nice@nice.org.uk
www.nice.org.uk

Sent via email

[REDACTED]

Wyeth Pharmaceuticals

22 June 2009

Dear [REDACTED]

Final Appraisal Determination: Bevacizumab (first line) sorafenib (first and second line) sunitinib (second line) and temsirolimus (first line) for the treatment of advanced and/or metastatic renal cell carcinoma

Thank you for your letter of 17 June.

However, after further careful consideration, the decision in the final scrutiny letter of 11 June still stands.

Yours sincerely

[REDACTED]

Appeal Committee Chair